


## AMENDMENTS TO THE CLAIMS

1. (Canceled)
2. (Currently Amended) The A compound of claim 1 having the formula I'':



I

and the geometrical isomers, enantiomers, diastereomers, and pharmaceutically acceptable salts thereof, wherein:

X and X' independently are hydrogen, halo, alkyl, alkenyl, alkynyl, alkoxy, trifluoromethyl or -  
(Y')<sub>m</sub>-W';

G and G' together form  $\text{HC}-\text{CH}$  or  $\text{C}=\text{C}$  ;

D is -CH= or =N-;

R<sup>1</sup> and R<sup>2</sup> independently are hydrogen or together are -(CH<sub>2</sub>)<sub>n</sub> in which n is equal to 0, 1, 2, or 3;

m and m' are independently 0 or 1;

Y and Y' are -L<sup>1</sup>- or -L<sup>2</sup>-V(Z)<sub>t</sub>-L<sup>3</sup>- in which t is 0 or 1;

L<sup>1</sup> is alkylene, alkenylene, alkynylene, or one of the foregoing in which one or more methylenes are replaced by -O-, -S-, -S(O)-, -S(O)<sub>2</sub>-, -N(Q)-, or -N(R<sup>3</sup>)-;

L<sup>2</sup> is (a) alkylene, alkenylene, alkynylene, or one of the foregoing in which one or more methylenes are replaced by -O-, -S-, -S(O)-, -S(O)<sub>2</sub>-, -N(Q')-, or -N(R<sup>4</sup>)-, or (b) -L<sup>4</sup>-C(O)-N(Q')- or -L<sup>4</sup>(Q')-, or (c) a direct bond;

L<sup>3</sup> is (a) alkylene, alkenylene, alkynylene, or one of the foregoing in which one or more methylenes are replaced by -O-, -S-, -S(O)-, -S(O)<sub>2</sub>-, -N(Q'')-, or -N(R<sup>5</sup>)-, or (b) a direct bond;

L<sup>4</sup> is (a) alkylene; alkenylene, alkynylene, or one of the foregoing in which one or more methylenes are replaced by -O-, -S-, -S(O)-, -S(O)<sub>2</sub>-, -N(Q'')-, or -N(R<sup>5</sup>)-, or (b) a direct bond;

V is (a) a divalent arene, a divalent heteroarene, or a divalent saturated heterocycle when t is 0, or (b) a trivalent arene or trivalent heteroarene when t is 1;

Q, Q', and Q'' independently are hydrogen, -AC(O)OR<sup>6</sup>, or -AC(O)NR<sup>6</sup>R<sup>7</sup>;

W and W' independently are -N(OM)C(O)N(R<sup>8</sup>)R<sup>9</sup>, -N(R<sup>8</sup>)C(O)N(OM)R<sup>9</sup>, -N(OM)C(O)R<sup>8</sup>, -C(O)NR<sup>8</sup>R<sup>9</sup>, or -C(O)OR<sup>8</sup>, provided that at least one of W and W' is -N(OM)C(O)N(R<sup>8</sup>)R<sup>9</sup>, -N(R<sup>8</sup>)C(O)N(OM)R<sup>9</sup>, or -N(OM)C(O)R<sup>8</sup>;

Z is -A''N(OM')C(O)N(R<sup>10</sup>)R<sup>11</sup>, -A''N(R<sup>10</sup>)C(O)N(OM')R<sup>11</sup>, -A''N(OM')C(O)R<sup>11</sup>, -A'C(O)N(OM')R<sup>11</sup>, -A'C(O)NR<sup>10</sup>R<sup>11</sup>, -A'C(O)OR<sup>10</sup>, halo, CH<sub>3</sub>, NR<sup>3</sup>R<sup>4</sup>, NR<sup>3</sup>C(O)R<sup>4</sup>, NO<sub>2</sub>, CN, CF<sub>3</sub>, S(O)<sub>2</sub>NR<sup>3</sup>R<sup>4</sup>, S(O)<sub>2</sub>R<sup>3</sup>, SR<sup>3</sup>, or S(O)R<sup>3</sup>;

A, A' and A'' independently are a direct bond, alkylene, alkenylene, alkynylene, yloalkylaryl, yloarylalkyl, or diyloalkylarene or one of the foregoing in which one or more methylenes are replaced with -O-, -NH-, -S-, -S(O)-, or -S(O)<sub>2</sub>- and/or one or more methylenes are replaced by =N-;

M and M' independently are hydrogen, a pharmaceutically acceptable cation, or a metabolically cleavable group; and

R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup>, and R<sup>11</sup> are independently hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, alkylaryl, alkylarylalkyl, or one of the foregoing in which one or more methylenes are replaced by -O-, -NH-, -S-, -S(O)-, or -S(O)<sub>2</sub>- and/or one or more methylenes are replaced by =N-;

provided that, other than the oxygens bound to the sulfurs in -S(O)- and -S(O)<sub>2</sub>-, when one or more methylenes are replaced with -O-, -NH-, -S-, -S(O)-, or -S(O)<sub>2</sub>- and when one or more methylenes are replaced with =N-, such replacement does not result in two heteroatoms being covalently bound to each other;


and further provided that when m is 0, W is not -C(O)NR<sup>8</sup>R<sup>9</sup>, or -C(O)OR<sup>8</sup>,

and further provided that in the substituent -AC(O)OOR<sup>6</sup>, R<sup>6</sup> cannot be hydrogen when A is a direct bond.

~~wherein the substituents are as defined in claim 1, and the geometrical isomers, enantiomers, diastereomers, and pharmaceutically acceptable salts thereof.~~

3. (Canceled)

4. (Currently Amended) The compound according to ~~claim 1~~ claim 2 having the formula **III**:



### III

wherein the substituents are as defined in ~~claim 1~~claim 2, and the geometrical isomers, enantiomers, diastereomers, and pharmaceutically acceptable salts thereof.

5-10. (Canceled)

11. (Previously Presented) A compound selected from the group consisting of compounds **10**, **32**, **53**, **54**, **61**, **73** and **74**.

12. (Previously Presented) A compound that is compound **32**.

13-15. (Canceled)

16. (Currently Amended) A compound according to ~~claim 1~~claim 2 wherein  
X and X' independently are hydrogen, halo, alkyl, alkenyl, alkynyl, alkoxy or trifluoromethyl;  
W is -N(OM)C(O)N(R<sup>8</sup>)R<sup>9</sup>, -N(R<sup>8</sup>)C(O)N(OM)R<sup>9</sup> or -N(OM)C(O)R<sup>8</sup>[;].

17. (Currently Amended) A compound according to claim 2~~claim 1~~ wherein  
L<sup>4</sup> is alkylene  
Z is -N(OM')C(O)N(R<sup>10</sup>)R<sup>11</sup>, -N(R<sup>10</sup>)C(O)N(OM')R<sup>11</sup>, -N(OM')C(O)R<sup>11</sup>, -A'C(O)N(OM')R<sup>11</sup>, -  
A'C(O)NR<sup>10</sup>R<sup>11</sup> or -A'C(O)OR<sup>10</sup>.

18. (Currently Amended) A compound according to claim 2~~claim 1~~ wherein  
X and X' independently are -H, halo, alkyl, alkenyl, alkynyl, alkoxy or trifluoromethyl;  
L<sup>4</sup> is alkylene  
W is -N(OM)C(O)N(R<sup>8</sup>)R<sup>9</sup>, -N(R<sup>8</sup>)C(O)N(OM)R<sup>9</sup> or -N(OM)C(O)R<sup>8</sup>;  
Z is -N(OM')C(O)N(R<sup>10</sup>)R<sup>11</sup>, -N(R<sup>10</sup>)C(O)N(OM')R<sup>11</sup>, -N(OM')C(O)R<sup>11</sup>, -A'C(O)N(OM')R<sup>11</sup>, -  
A'C(O)NR<sup>10</sup>R<sup>11</sup> or -A'C(O)OR<sup>10</sup>.

19. (Currently Amended) A compound according to claim 2~~claim 1~~ wherein when M or M' is a metabolically cleavable group this is selected from an organic or inorganic anion, a pharmaceutically acceptable cation, acyl, alkyl, phosphate, sulfate and sulfonate,  $\text{NH}_2\text{C}(\text{O})-$  or  $(\text{alkyl})\text{OC}(\text{O})-$ .
20. (Original) A compound according to claim 19 wherein acyl is  $(\text{alkyl})\text{C}(\text{O})$ , including acetyl, propionyl and butyryl.
21. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound according to claim 2~~claim 1~~.
22. (Canceled)
23. (Currently Amended) A method of treating asthma, the method comprising administering to a patient suffering from asthma an amount of a compound according to claim 2~~claim 1~~ sufficient to reduce or eliminate the asthma.
24. (Canceled)